ABSTRACT-Ricin A-chain, the toxic subunit of the potent plant toxin ricin, has been isolated by affinity chromatography and conjugated via a disulfide linkage to affinity-purified goat anti-carcinoembryonic antigen (CEA) antibody. Such conjugates retained the integrity of their antibody-combining site, as demonstrated by the ability to displace 1251-labeled anti-CEA antibody bound to CEA-positive cell lines. In addition, such conjugates retained A-chain activity, producing inhibition of The use of presently available antitumor agents is limited to a major extent by their nonspecific cytotoxic effect on normal cells. The concept of increasing the selectivity of antitumor agents by linkage of "antitumor" antibodies dates back nearly a century (1) and has been the subject of intense and imaginative investigation for the past 3 decades. These investigations have been the subject of several recent reviews (2-4). Although the present understanding of the genetic heterogeneity and clonal evolution of human tumor cell populations makes "magic bullet" therapy problematic, nevertheless, a combination of the selectivity of antibody with the lethal effects of toxins offers the promise of antitumor therapy with increased selectivity. Although early results gave only marginal specificity for target cells, more recent efforts that utilized improved methods of chemical coupling have demonstrated greater success. Furthermore, two recent developments have caused reassessment of the use of such "immunotoxins." The first development is the prospective availability of hybridoma-derived homogenous antibodies, with defined specificity, avidity, and class, against tumor-related antigens (5). The second advance is a greatly improved understanding of the structure and mechanism of action of the potent toxic proteins ricin, abrin, diphtheria toxin, and others (6-8).
ABSTRACT-Ricin A-chain, the toxic subunit of the potent plant toxin ricin, has been isolated by affinity chromatography and conjugated via a disulfide linkage to affinity-purified goat anti-carcinoembryonic antigen (CEA) antibody. Such conjugates retained the integrity of their antibody-combining site, as demonstrated by the ability to displace 1251-labeled anti-CEA antibody bound to CEA-positive cell lines. In The use of presently available antitumor agents is limited to a major extent by their nonspecific cytotoxic effect on normal cells. The concept of increasing the selectivity of antitumor agents by linkage of "antitumor" antibodies dates back nearly a century (1) and has been the subject of intense and imaginative investigation for the past 3 decades. These investigations have been the subject of several recent reviews (2) (3) (4) . Although the present understanding of the genetic heterogeneity and clonal evolution of human tumor cell populations makes "magic bullet" therapy problematic, nevertheless, a combination of the selectivity of antibody with the lethal effects of toxins offers the promise of antitumor therapy with increased selectivity. Although early results gave only marginal specificity for target cells, more recent efforts that utilized improved methods of chemical coupling have demonstrated greater success. Furthermore, two recent developments have caused reassessment of the use of such "immunotoxins." The first development is the prospective availability of hybridoma-derived homogenous antibodies, with defined specificity, avidity, and class, against tumor-related antigens (5) . The second advance is a greatly improved understanding of the structure and mechanism of action of the potent toxic proteins ricin, abrin, diphtheria toxin, and others (6) (7) (8) .
Previous investigators have suggested that antibody delivery systems for cytotoxins are most successful when they utilize extremely toxic substances (9-11). The toxic proteins we used satisfy such a requirement, in that their toxic moieties act enzymatically, rather than stoichiometrically, to inhibit protein synthesis (6) (7) (8) (9) . Thus only a few molecules of these effector subunits are capable of producing cytotoxicity if entry is gained to the cytoplasm. However, utilization of the complete toxin incurs the risk of nonspecific toxicity. To circumvent this difficulty, we, (12) and other investigators (13) (14) (15) (16) (17) have explored the selective toxicity of conjugates of a specific antibody and the toxic subunit of ricin. Ricin, a potent protein inhibitor derived from the castor bean, has proved exceptionally adaptable to this approach, in that the toxin molecule shows segregation of biologic function into a) a binding (or B) chain that adheres to galactose moieties on the cell surface, and b) an activity (or A) chain that enzymatically inactivates ribosomes (8) . These investigations have shown that it is possible to substitute specific antibody or antibody fragments as fraudulent Bchains, thereby producing conjugates of high cytotoxic potential, specific for cells that bear the appropriate antigen.
The present report extends these observations to conjugates constructed with antibodies directed against the oncofetal protein CEA. This operationally defined antigen describes a family of glycoproteins found on the surfaces of a variety of human cancers (18) , and this family may be an appropriate target for clinically relevant immunotoxins. Isolation of ricin A-chain.~Ricin A-chain was isolated from the parent toxin (Sigma Chemical Co., St. Louis, Mo.; EY Laboratories, San Mateo, Calif.) by an adaptation of a previously described method (23) . The toxin was reduced by the addition of 2-mercaptoethanol to a final concentration of 5%, incubated for 12 hours at 23°C, and centrifuged at 3,000 rpm for 15 minutes. The supernatant was then applied to a column of lactose-substituted agarose (Selectin 12; Pierce Chemical Co., Rockford, II!.). The isolated Achain was eluted with PBS that contained 0.1 % 2-mercaptoethano!. Further traces of contaminating ricin and Bchain were then removed by passage over a Sepharose 4B column pretreated with 1 N acetic acid for 24 hours and washed extensively with elution buffer (24) . After repeated elution of the A-chain, the peak tubes were pooled, dialyzed against PBS for removal of residual 2-mercaptoethanol, and concentrated by ultrafiltration (PMlO membrane; Amicon Corp., Lexington, Mass.). The resulting product was further purified by passage over a Sephadex G-25 column. The homogeneity of the A-chain prepared in this manner was assessed by SDS-PAGE by a previously described method (fig. 1.) (25, 26) . The integrity of A-chain protein inhibition was assessed in a rabbit reticulocyte lysate system (Bethesda Research Laboratories, Inc., Gaithersburg, Md.). Successfully purified A-chain demonstrated an ID50 of e 4 C] leucin e incorporation of 1-5X 10-7 Min WiDr cells in the system described above, compared to the ID50 of intact ricin of zx 10-10 M. Additional ricin A-chain was obtained commercially from EY Laboratories.
MATERIALS AND METHODS

Cell
Synthesis of ricin A-chain-antibody conjugates.~Affinity-puri fied a.itibody, at a concentration of2.5 mg/ml, was dialyzed against PBS for 24 hours and then reacted with a 25-fold molar excess of the bifunctional coupling reagent N-succinimidyl-3 -(2 -pyridyldithio) propionate (Pharmacia, Fine Chemicals, Piscataway, N.].) (27) . Reaction continued at 23°C for 30 minutes, after which time reaction products were again dialyzed against PBS for an additional 24 hours. The resulting protein was then reacted with a two times molar excess of ricin A-chain. The progress of the reaction was monitored by release of pyridine-2-thione (increased absorbance at 343 nm). Reaction products were then separated on a molecular sizing column (Sephadex G-100). Progress of the reaction was confirmed by SDS-PAGE (fig.
1.).
125I_Iabeled anti-CEA antibody binding assay.~To measure specific binding of 125I-labeled anti-CEA antibody by the various cell lines, we performed competitive binding experiments with radioiodinated anti-CEA antibody, unreacted antibody, and conjugate in this manner: 1 ml of the desigJNCl, VOL. 69, NO.4, OCTOBER 1982 nated cell line (at 4X 10 4 cells/ml) was spun to a firm pellet (2,000 rpm for 10 min). The supernatant was removed, and 125I_Iabeled anti-CEA antibody (lO5 cpm/0.05 ml) was added to the pellet. The cells were then incubated at 23°C for 30 minutes, washed twice with 1 ml of PBS, and then pelleted and counted. The absolute number of counts bound was obtained by the subtraction of counts in tubes containing radiolabeled antibody alone from counts in tubes containing label and cells. In experiments that demonstrated the integrity of the antibody combining site, cells were preincubated for 30 minutes at 23°C with unlabeled anti-CFE antibody or conjugate in the designated amount and then treated in the above manner.
Assay of protein inhibiti()n.~Confluent WiDr cells were removed with a T-75 flask with 0.25% trypsin and 0.02'1c· EDTA. The cells were then suspended in leucine-free medium (MEM with 10% FCS and 1% antibiotics) and seeded into microtiter wells (2X 10 4 cells/well). The cells were incubated (after appropriate additions of conjugate, ricin, ricin A-chain, or unconjugated antibody to achieve the specified levels) for 16 hours at 37°C in 5% CO2, treated with a 3-hour pulse of e 4 C] leucine (New England Nuclear Corp., Boston, Mass.), and harvested onto filter disks with a Mash II cell harvester. Incorporation of radioactivity into the cells was measured by scintillation counting after extensive washing on a glass fiber filter.
Reversal of toxicity by free CEA.~Specific anti-CEA conjugate (2X 10-7 M) was incubated for 1 hour with free CEA (2X 10-7 M) and then added to Wi Dr cells to a final conjugate concentration of 1X 10-
leucine incorporation was assayed in the manner described and was compared to that of unreacted conjugate, free antigen, or controls.
Reversal of toxicity by free antibody.~Confluent Wi Dr cells were removed from a T-75 flask with 0.25% trypsin in 0.020/< EDTA. The cells were resuspended in leucine-free medium (EMEM, 10% FCS, and antibiotics) at a concentration of 10 5 cells/m!' The cells were then centrifuged (2,000 rpm for 5 min) to a pellet, and the supernatant was removed.
Unreacted anti-CEA antibody or nonspecific antibody was added to the pellet at a concentration of 2.0X 10-5 M (2-log excess over conjugate). Similarly handled cells were treated with an equal volume of PBS alone. The cells were then incubated at 23°C for 1 hour, and conjugate (l X 10-7 M) was added to PBS and antibody-treated cells. After a subsequent I-hour incubation at 23°C, the cells were washed with medium and plated into microtiter wells.
[14C]leucine incorporation was then determined in the manner described above.
RESULTS
PAGE of Ricin A-Chain-Anti-CEA Antibody Conjugates
Figure 1 presents PAGE of unreacted antibody, free Achain, conjugate, and conjugate after reduction. These dual bands of isolated A-chain ( fig. 1: A, B, I , J) were seen in both A-chain preparations obtained from the parent toxin, by the above-cited method, and in that obtained commercially. The appearance of homologous A-chains of these Binding of Anti-CEA Antibody-Ricin A-Chain Conjugates by CEA-Positive Cell Lines molecular masses (30,000 and 33,000 daltons) following reduction of the parent toxin has been previously described (28) . The affinity-isolated antibody (G) is a broad band at a molecular mass of approximately 150,000 daltons, whereas the conjugate preparation (C and E) shows an increase in the molecular mass over that of antibody alone, suggesting the addition of A-chain to the antibody. Reappearance of the free A-chain bands following DTT treatment of the conjugate (D and F) confirms successful synthesis of the conjugate.
HT-29 adenocarcinoma cells produce small amounts of CEA during growth in vitro and have been shown to bind anti-CEA antibody, both by immunofluorescence and by the binding of radiolabeled antibody (29, 30) . WiDr, a recently characterized cell line, produces a moderate amount ofCEA (118 ng/10 6 cells in 10 days: American Type Culture Collection Information Sheet) compared to that produced by other colorectal adenocarcinoma cell lines in vitro (22) . fined by binding of radiolabeled antibody not displaceable by preincubation with 10-6 M unlabeled specific antibody. Thus by this method of analysis, these cell lines express little or no CEA on their cell membrane. In contrast, the adenocarcinoma cell lines showed specific binding of 1251-labeled anti-CEA antibody. The moderate CEA producer Wi Dr bound more radiolabeled antibody than the low CEA producer HT-29. Similar in vitro binding of radiolabeled anti-CEA antibody by the HT-29 cell line has been previously described by Tompkins and colleagues (30) .
To demonstrate retention of antigen-binding activity of the anti-CEA-ricin A-chain conjugates, we compared the ability of these conjugates to prevent binding of 125 1_ labeled anti-CEA antibody to that of unreacted antibody (table 2) . This displacement was concentration related, with 50% of bound counts displaced by pretreatment with a concentration of 5-7x 10-7 M conjugates and 3-5X 10-7 M unreacted antibody in the two adenocarcinoma cell lines. Thus the conjugate showed comparable or slightly reduced reactivity with cell surface CEA as free antibody, thereby chain-antibody conjugate was mediated by the CEA combining site of the antibody moiety of the conjugate, we showed reversal of cytotoxic effect with both fluid-phase antigen and excess free antibody. Text-figure 3A demonstrates complete reversal of the inhibitory action of the conjugates by preincubation with equimolar amount of fluid-phase antigen for I hour. No precipitation occurred during this incubation. Simultaneous addition of fluid-phase antigen produced no reversal of cytotoxic effect. Preincubation of the nonspecific conjugate with fluid-phase antigen under identical conditions had no effect on its toxicity. Similar reversal of conjugate inhibitory effect was demonstrated with excess free antibody (text- fig. 3B ). A 2-log antibody excess pretreatment was required for complete reversal, with lesser effects seen with I-log excess and equimolar amounts. Nonspecific antibody pretreatment had no effect on conjugate action. To demonstrate that the increased toxicity of the ricin ADose-response curves of inhibition of C 4 C ]leucin e incorporation in WiDr CEA-positive cells are presented in textfigure 1. The ID 50 for intact ricin in this system was zx M. The ID 50 levels for whole ricin in the presence of serum proteins, which inhibit its binding, may be overestimates. Conjugates prepared in the above manner had an ID50 of8X 10-9 M or approximately, 2.5% that of the native toxin. Levels of 5X 10-8 M completely inhibited [14C]leucine incorporation. The A-chain itself, or mixed with unconjugated antibody, had an ID 50 of 3X 10-7 M or 0.1 % of the parent toxin. Free antibody alone gave no inhibition of protein synthesis in this system. The conjugate was, therefore, 40 times more effective than free A-chain in producing an inhibition of protein synthesis in this system. In contrast, the conjugate was not more toxic than free A-chain in the melanoma cell line G-361, which bears no CEA.
To determine whether the inhibition of C 4 C] leu cin e incorporation was associated with cytotoxic effect, we examined the effect of specific conjugate, free A-chain, and a noncovalent mixture of A-chain and antibody on adenocarcinoma proliferation in vitro. WiDr cells were seeded as above with the exception that complete medium (EMEM with leucine, 10% FCS, and 1% antibiotics) rather than leucine-free medium was used, and daily cell enumerations were obtained by a Coulter counter. The number of untreated cells increased five times over 5 days. At a level of 5X 10-8 M conjugate, 50% inhibition of cellular proliferation at 5 days was seen. Similar degrees of inhibition required levels of I X 10-6 M A-chain or I X 10-6 M A-chain plus antibody. Thus the conjugate demonstrated the capacity to function as a potent cytotoxin against cells bearing the appropriate antigen.
Text-figure 2A compares protein inhibition in WiDr versus the control cell line human melanoma G-361. G-361 cells showed similar sensitivity to protein synthesis inhibition by ricin and ricin A-chain as WiDr in that system. Again, the specificity of conjugate effect was approximately eightfold at the ID 50 concentration.
In text-figure 2B the toxicity of specific anti-CEA conjugate is compared with that of a conjugate prepared with nonspecific antibody (goat anti-human IgG, affinity purified). This nonspecific antibody was more toxic than free A-chain (three times at the ID5o) but still eightfold less toxic than specific conjugates at the ID50 level. In contrast, the nonspecific conjugate showed equivalent toxicity (ID 50 :::::I X 10-7 M) to both the CEA-bearing and CEA-negative cell lines. 
DISCUSSION
The demonstration that specific antibody or antibody fragments can serve as alternate binding units for the toxic A-chains of ricin and diphtheria toxin (12-16) and impart antigen-dictated selective cytotoxicity to these conjugates has rekindled interest in such immunotoxins as selective antitumor agents. Most attempts to date have focused on lymphocyte-differentiation antigens (16) , surface IgG on Blymphocytes (12, 13), or artificially introduced antigens (15), except one study that described the use of a monoclonal antibody directed against an antigen that was reported specific for colorectal adenocarcinoma (14) .
CEA was first described by Gold and Freedman (31) in 1965 as an antigen associated with embryonic and neoplastic gastrointestinal tissues. A radioimmunoassay for CEA was reported in 1969. The presence of detectable quantities of CEA in adult serum was originally thought to be specific for the presence of cancer, but recent evidence indicates that CEA may be elevated in many benign conditions as well (18) . In addition, CEA levels are commonly elevated in many cancers of nondigestive tract origin (32) . CEA is operationally defined by reagents similar to those originally used by Gold and Freedman (31) and is immunochemically complex. Evidence now suggests that CEA describes a family of related glycoproteins, with a wide range of molecular weights and carbohydrate content (33) . Polar redistribution of CEA expressed on the surfaces of human intestinal carcinoma cells in culture induced by specific antibody has been described (29) .
The inhomogeneity of the CEA, its shedding by malignant cells, and its wide distribution may limit the usefulness of such conjugates as described here. However, an extensive literature has documented the successful in vivo tumor localization of radiolabeled anti-CEA antisera in both animal and clinical models (34) and possible therapeutic utility of such conjugates (35) . Therefore, despite the limitations of this system noted above, CEA remains an attractive antigenic "target" for immunotoxins.
Previous investigators have described CEA antiserum as a carrier of cytotoxins. Shearer et al. (36) reported specific cytotoxicity of glucose oxidase-anti-CEA antisera for human colon carcinoma cells . This system required subsequent treatment with glucose, iodide, and lactoperioxidase for production of specific iodination of cell membranes, and, therefore, is much more cumbersome than the system described here. Belles-Isles and Page (37) have described selective cytotoxicity of daunomycin-anti-CEA conjugates for a human colon carcinoma cell line. Similarly, Johnson et al. (38) have recently described a conjugate of sheep anti-CEA immunoglobulin and the anticancer drug vindesine, which was cytotoxic for human cancer cells in vitro. The optimal cytotoxin for antibody conjugation will require further study, but the relative lack of cytotoxicity of isolated ricin A-chain makes it an attractive candidate.
The increased toxicity of ricin A-chain after conjugation to anti-CEA heteroantibody toward human adenocarcinoma cells is significantly less than that described with other tumor systems. For example, Raso et al. (23) have recently reported a conjugate of ricin A-chain and monoclonal antibody directed against the common antigen expressed on human lymphoblastic leukemia cells. This conjugate produced 50% inhibition of proliferation in culture of a human leukemia cell line bearing the appropriate antigen at levels of2XlO-1o M. Similarly, Blythman et al. (16) have described the construction of a conjugate of ricin A-chain and monoclonal IgM antibody directed against the Thy 1.2 differentiation antigen of mouse T-cells. This conjugate's specificity factor (conjugate:ricin A-chain) was 5,000, more than 100 times that described in our system.
The explanation for the relative lack of potency of our conjugate is unclear but may be related to a variety of factors. First, the use of heteroantibody as compared to monoclonal antibody may decrease the molar potency of the conjugates. With this prospect in mind, the use of monoclonal anti-CEA antibody in our system would be of interest. Second, and perhaps most important, CEA may be much less efficient in mediating A-chain entry into the cytoplasm than the above-cited antigens. Finally, our method of A-chain coupling may not be the optimal approach, and alternate methods of conjugation or delivery may yield superior results (3). 
